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Abstract
Objective: To examine the distribution of risks for fetal triso-
mies after first-trimester combined screening in twins and to 
investigate different strategies for clinical implementation 
of cell-free DNA (cfDNA) testing. Methods: We retrospective-
ly analyzed all twin pregnancies undergoing first-trimester 
combined screening over a 10 years’ period. The population 
was stratified according to various risk cut-offs, and we ex-
amined different screening strategies for implementation of 
cfDNA testing in terms of impact on invasive testing rate, 
cfDNA test failure rate, and economic costs. Results: We in-
cluded 572 twin pregnancies: 480 (83.92%) dichorionic and 
92 (16.08%) monochorionic. Performing a first-line com-
bined screening and offering cfDNA testing to the group 
with a risk between 1 in 10 and 1 in 1,000, would lead to an 
invasive testing rate of 2.45%, and cfDNA testing would be 
performed in 22.20% of the population. This strategy would 
be cost-neutral compared to universal combined screening 
alone. Conclusions: First-trimester combined screening re-
sults can be used to stratify twin pregnancies into different 
risk categories and select those that could be offered cfDNA 
testing. A contingent screening strategy would substantially 
decrease the need for invasive testing in twins and it would 
be cost-neutral compared to combined testing alone.
© 2018 S. Karger AG, Basel
Introduction
The combination of maternal age, fetal nuchal trans-
lucency (NT) thickness, maternal serum free β-human 
chorionic gonadotropin, and pregnancy-associated plas-
ma protein A in the first trimester of pregnancy is a well-
established method of screening for trisomies in single-
ton gestations with reported detection rates (DR) of 90, 
97, and 92% for trisomy 21, 18, and 13, for an overall false-
positive rate (FPR) of 4% [1]. Combined test (CT) in twin 
pregnancies has been evaluated in few studies [2–4], and 
a recent meta-analysis showed that the performance is 
similar to singletons, with a DR for trisomy 21 of 89.3% 
and an FPR of 5.4% [5].
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Cell-free DNA (cfDNA) testing in maternal blood has 
been recently introduced as a new method of screening 
for trisomies 21, 18, and 13, and the published studies on 
singleton pregnancies have consistently reported DR in 
the range of 99% or more, with an FPR of 0.1–0.3% and 
a test failure rate of 0.9–4.9% [6–9]. Different strategies 
for clinical implementation of cfDNA testing in single-
ton pregnancies, as universal screening or contingent to 
the results of the CT, are currently under investigation 
[10–12]. Few studies have examined the performance of 
cfDNA testing in twin pregnancies, and the preliminary 
results showed similar DR and FPR compared to single-
tons [7, 13–15]. However, the reported test failure rate 
after the first blood sample appears to be higher than in 
singletons, with a potential impact on the overall perfor-
mance of screening, but there is a wide variation from 2.9 
to 9.4% among the few published studies [13–15]. In ad-
dition, the ultrasound component of the CT is essential 
to determine chorionicity and to identify structural de-
fects detectable in the first trimester, with major clinical 
implications for subsequent management [16, 17]. 
Therefore, investigation into possible ways for imple-
mentation of CT and cfDNA testing together is impor-
tant to maximize DR and to minimize invasive testing 
rate in screening for common trisomies, retaining the 
ability to obtain the additional clinical information pro-
vided by the CT.
The aim of this study was to examine the distribution 
of risks after first-trimester CT in twin pregnancies and 
to investigate different strategies for clinical implementa-
tion of cfDNA testing.
Methods
This retrospective, multicenter study included twin pregnan-
cies that underwent first-trimester combined screening between 
March 2005 and September 2015 at three Italian Fetal Medicine 
Centers (Careggi University Hospital, Florence; Piero Palagi Hos-
pital, Florence; Pisa University Hospital, Pisa). Written consent 
was obtained from all patients participating in the study.
Screening was based on the combination of maternal age, NT 
thickness measured between 11+0 and 13+6 weeks, and maternal 
serum free β-human chorionic gonadotropin and pregnancy-asso-
ciated plasma protein A measurements between 9+0 and 13+6 
weeks. Chorionicity was determined by ultrasound demonstrating 
the lambda or T sign. Pregnancy dating was based on the crown-
rump length of the larger twin. Ultrasound scans were carried out 
by trained sonographers accredited by the Fetal Medicine Founda-
tion (FMF London, UK; www.fetalmedicine.org [18]). The bio-
chemical markers were analyzed using DELFIA® Xpress system 
(Perkin Elmer, Waltham, MA, USA) or Kryptor analyzer (BRA-
HAMS® AG, Berlin, Germany). Ultrasound and laboratory data 
were entered into the FMF software to calculate the estimated risk 
for trisomies 21, 18, and 13. For dichorionic twins, the individual 
risk for each fetus was considered, whereas for monochorionic 
twins an overall pregnancy risk was calculated based on the aver-
age of the risks of the two fetuses. 
The test was considered positive if the risk was ≥1: 250, and all 
patients with a positive result for at least one twin were offered in-
vasive testing as per local clinical guidelines. Fetal karyotyping was 
carried out by chorionic villous sampling (CVS) or amniocentesis. 
For patients who did not undergo invasive testing, neonatal out-
come and information on clinical phenotype were obtained from 
computerized medical records or by telephone interviews.
The dataset was analyzed examining firstly the distribution of 
the entire cohort of pregnancies, according to their risk after com-
bined screening. Subsequently, different intermediate risk groups 
were identified based on various risk cut-off ranges. The impact of 
different screening strategies in terms of invasive testing rate, cf-
DNA test failure rate, and economic costs was evaluated. The in-
vasive testing rates of combined screening were calculated based 
on predefined risk cut-offs. The number of invasive procedures 
following a high-risk result from cfDNA testing was calculated as-
suming that the test would have detected all cases of trisomy 21, 
18, and 13 with no false-positive results. cfDNA test failure rate was 
calculated as the mean of the published test failure rates after the 
first blood sample in twin pregnancies (5%) [13–15]. In case of 
cfDNA test failure, it was assumed to offer a second testing to every 
patient, considering to obtain a result after the second test in 50% 
of cases, as the mean of published data [13–15]. The economic 
costs were calculated based on regional public health reimburse-
ments as follows: NT scan = EUR 51; maternal biochemistry = 
EUR 32; CVS or amniocentesis with genetic analysis = EUR 465 (1 
sample) for monochorionic and EUR 894 (2 samples) for dichori-
onic twins; cfDNA test (inclusive of laboratory and clinical work-
flow) = EUR 347.
Table 1. Maternal and pregnancy characteristics of the population 
of 572 twin pregnancies
Maternal age, years 35 (32–38)
Maternal weight, kg 61 (55–68)
ART conception 268 (46.85)
Ethnicity
White 558 (97.55)
African 8 (1.39)
East Asian 2 (0.35)
South Asian 2 (0.35)
Mixed 2 (0.35)
Smokers 57 (9.96)
Gestational age at ultrasound, days 85 (83–87)
CRL, mm 57.40 (53.20–62.00)
NT, mm 1.60 (1.37–1.89)
Chorionicity
Dichorionic 480 (83.92)
Monochorionic 92 (16.08)
Data are presented as n (%) or median (interquartile range); 
ART, assisted reproductive technology; CRL, crown rump length; 
NT, nuchal translucency.
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Statistical analysis was performed using SPSS version 23.0 
(SPSS Inc., Chicago, IL, USA) and Microsoft Office Excel (Micro-
soft Corp., Redmond, WA, USA). Data regarding continuous vari-
ables were expressed as median and interquartile range (IQR); cat-
egorical variables were expressed as number and percentages.
Results
The study population consisted of 572 twin pregnancies 
(1,144 fetuses) that underwent first-trimester screening. 
Table 1 summarizes maternal and pregnancy characteris-
tics of the study population. The median maternal age was 
35 years (IQR 32–38 years) and the median gestational age 
at ultrasound was 12.14 (IQR 11.85–12.43) weeks. In 268 
(46.85%) cases, the pregnancy was obtained through assist-
ed reproductive techniques. There were 480 (83.92%) di-
chorionic and 92 (16.08%) monochorionic pregnancies. 
Fetal karyotype and/or neonatal phenotype was normal in 
1,139 (99.56%) cases and abnormal in the remaining 5 
(0.44%). The abnormal group included 5 fetuses, each from 
a different dichorionic pregnancy, two with trisomy 21 and 
one case each of trisomy 18, trisomy 13, and 47XY+8/46XY 
mosaicism (diagnosed at CVS and confirmed by amniocen-
tesis). In all chromosomally abnormal cases, the risk for tri-
somy 21, 18, or 13 after combined screening was ≥1 in 250. 
No additional cases of aneuploidies were found on postna-
tal follow-up in cases with a risk < 1 in 250.
Table 2 shows the distribution of pregnancies with dif-
ferent fetal karyotypes according to the highest combined 
risk and NT thickness within each twin pair. In Table 3, 
we reported the proportion of pregnancies included be-
tween an upper and a lower risk cut-off, defining various 
intermediate risk groups that could be offered cfDNA 
testing. Subsequently, we examined different screening 
strategies with the associated invasive testing rate, cfDNA 
test failure rates, and economic costs (Table 4). The strat-
egy of performing a first-line combined screening, offer-
ing cfDNA testing to the group of pregnancies with a risk 
between 1 in 10 and 1 in 1,000, would require that an in-
vasive diagnostic procedure is carried out in 2.45% of the 
cases and that cfDNA testing is offered to 22.20% of the 
population. This strategy would be cost-neutral com-
pared to universal combined screening alone. In addition, 
the overall cfDNA test failure rate would be lower com-
pared to universal cfDNA screening (1.05 vs. 5.1%, re-
spectively; p < 0.05) because the test would be offered to 
a smaller proportion of the population.
Discussion
The main findings of this study are that firstly com-
bined screening results can be used to stratify the popula-
tion of twin pregnancies into different risk categories, to 
Table 2. Distribution of twin pregnancies with different fetal karyotypes according to the highest combined risk 
and NT thickness within each twin pair in the study population of 572 twin pregnancies
Risk cut-off
Total (n = 572)
Normal 
(n = 567)
Trisomy 21
(n = 2)
Trisomy 18
(n = 1)
Trisomy 13
(n = 1)
Other aneuploidies
(n = 1)
1 in 10 3 (0.53%) 0 0 0 0
1 in 20 10 (1.76%) 0 0 0 0
1 in 30 15 (2.66%) 0 1 (100%) 1 (100%) 0
1 in 40 24 (4.23%) 1 (50%) 1 (100%) 1 (100%) 0
1 in 50 30 (5.29%) 1 (50%) 1 (100%) 1 (100%) 0
1 in 100 38 (6.70%) 1 (50%) 1 (100%) 1 (100%) 1 (100%)
1 in 250 62 (10.93%) 2 (100%) 1 (100%) 1 (100%) 1 (100%)
1 in 500 81 (14.23%) 2 (100%) 1 (100%) 1 (100%) 1 (100%)
1 in 1,000 125 (22.05%) 2 (100%) 1 (100%) 1 (100%) 1 (100%)
1 in 1,500 169 (29.81%) 2 (100%) 1 (100%) 1 (100%) 1 (100%)
1 in 2,000 211 (37.21%) 2 (100%) 1 (100%) 1 (100%) 1 (100%)
1 in 2,500 239 (42.15%) 2 (100%) 1 (100%) 1 (100%) 1 (100%)
1 in 3,000 267 (47.09%) 2 (100%) 1 (100%) 1 (100%) 1 (100%)
Nuchal translucency
≥4.0 mm 5 (0.88%) 1 (50%) 1 (100%) 0 0
≥3.5 mm 6 (1.06%) 1 (50%) 1 (100%) 1 (100%) 1 (100%)
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select those that could be offered cfDNA testing. Second-
ly, a contingent screening strategy would substantially 
decrease the need for invasive testing in twins and it 
would be cost-neutral compared to combined testing 
alone.
It is generally agreed that every pregnant woman 
should be offered an ultrasound examination in the first 
trimester of pregnancy [19]. The 11–13 weeks’ scan has 
become part of routine obstetric care because it can iden-
tify about half of the cases with major structural abnor-
malities and all of those with increased NT thickness, 
which are established clinical risk factors for adverse fetal 
outcome [17, 19]. In twin pregnancies, ultrasound is par-
ticularly important because it allows to determine chori-
onicity, with major implications on pregnancy follow-up 
and outcome [16]. The inclusion of maternal serum bio-
chemistry, with appropriate adjustments for dichorionic 
and monochorionic twin pregnancies, provides a more 
accurate risk assessment for major trisomies compared to 
NT thickness alone [5]. 
A major advantage of cfDNA testing is that it is as-
sociated with a very low FPR of about 0.3% if the test is 
used only in screening for trisomies 21, 18, and 13 [7]. 
However, it does not detect all the possible chromosom-
al abnormalities; for example, the case of 47XY+8/46XY 
mosaicism present in this study would not have been 
detected using cfDNA testing only [7]. Moreover, cf-
DNA analysis does not provide any information on fetal 
structural development, and the results should always be 
interpreted in combination with ultrasound findings. 
For example, if a major structural defect or a very large 
NT (typically ≥3.5 mm) is detected by ultrasound, the 
option of invasive testing should be discussed irrespec-
tive of the results of cfDNA analysis [17]. In addition, 
the few published studies on cfDNA testing in twin 
pregnancies showed a higher test failure rate compared 
Table 4. Impact of different screening strategies on cfDNA failure rates, invasive testing rates, and economic costs based on our popula-
tion of 572 twin pregnancies
Strategy Indication for invasive testing cfDNA test cfDNA test 
failure
Invasive test Cost, EUR
Universal combined test Risk ≥1 in 250 – – 67 (11.71%) 104.800
Universal cfDNA test cfDNA high risk result or no  
result after 2 cfDNA tests
572 (100%) 29 (5.10%) 18 (3.15%) 223.781
Universal ultrasound + cfDNA test NT >3.5 mm and/or cfDNA high
risk result or no result after 2 
cfDNA tests
572 (100%) 29 (5.10%) 25 (4.37%) 249.773
Universal combined test and cfDNA 
test if the risk is between 1 in 10 
and 1 in 1,000
Combined risk >1 in 10 and/or 
NT >3.5 mm and/or cfDNA high
risk result or combined risk ≥1 in
250 and no result at cfDNA
127 (22.20%) 6 (1.05%) 14 (2.45%) 102.774
Table 3. Distribution of pregnancies in the study population according to an upper and lower risk cut-off after combined screening, 
defining different intermediate-risk groups that could be offered cfDNA testing in a contingent strategy
Lower risk cut-off
Upper risk cut-off 1 in 500 1 in 1,000 1 in 1,500 1 in 2,000 1 in 2,500 1 in 3,000
1 in 10 83 (14.51%) 127 (22.20%) 171 (29.90%) 213 (37.24%) 241 (42.13%) 269 (47.03%)
1 in 20 76 (13.29%) 120 (20.98%) 164 (28.67%) 206 (36.01%) 234 (40.91%) 262 (45.80%)
1 in 30 69 (12.06%) 113 (19.76%) 157 (27.45%) 199 (34.79%) 227 (39.69%) 255 (44.58%)
1 in 40 59 (10.31%) 103 (18.01%) 147 (25.70%) 189 (33.04%) 217 (37.94%) 245 (42.83%)
1 in 50 53 (9.27%) 97 (16.96%) 141 (24.65%) 183 (31.99%) 211 (36.89%) 239 (41.78%)
1 in 100 44 (7.69%) 88 (15.38%) 132 (23.08%) 174 (30.42%) 202 (35.31%) 230 (40.21%)
1 in 250 19 (3.32%) 63 (11.01%) 107 (18.71%) 149 (26.05%) 177 (30.94%) 205 (35.84%)
Data are presented as n (%).
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to singletons [13–15] and the test is still expensive at the 
time of writing, with a local cost of about EUR 350 in-
clusive of laboratory and counselling workflow. These 
clinical and economic considerations do not support the 
use of cfDNA testing as a stand-alone universal screen-
ing method. 
Our data showed that first-trimester combined screen-
ing can be used to identify subgroups of the population 
of twin pregnancies based on the calculated patient-spe-
cific risk for common trisomies. Different cut-off ranges 
can be used to define the intermediate risk group that 
could be offered cfDNA testing (Table 3). In the estima-
tion of the performance of the different screening strate-
gies, a minimum invasive testing rate should always be 
set based on established clinical criteria that define the 
very-high-risk group, such as a combined risk ≥1 in 10, 
NT ≥3.5 mm and/or other major ultrasound anomalies. 
Based on our data, the strategy of offering cfDNA testing 
to patients with a risk between 1 in 10 and 1 in 1,000 after 
combined screening would produce a significant reduc-
tion in the invasive testing rate (11.71 vs. 2.45%). In this 
strategy, it was considered to offer an invasive procedure 
to patients with no results at cfDNA testing only if the 
CT was positive (risk ≥1: 250) for at least one twin. The 
implementation of cfDNA testing contingent to the re-
sults of combined screening has been shown to be effec-
tive in reducing the invasive testing rate in singleton 
pregnancies [11, 12, 20]. In addition, a recent study 
showed that the results of combined screening are useful 
in the clinical management of cases with a cfDNA test 
failure [21].
Economic budget analysis in the field of prenatal 
screening should take into account the costs of the differ-
ent required technologies and equipment (i.e., ultra-
sound machines, biochemical instruments, DNA se-
quencers, needles, culture media, etc.), as well as the costs 
needed to run the service, such as personnel hours need-
ed to perform the different analyses and to provide ap-
propriate parents’ counselling. In Italy, these costs are 
established at a regional level by the local healthcare au-
thorities. In our population, contingent screening with 
cfDNA testing to the 1 in 10–1 in 1,000 risk group would 
be cost-neutral compared with combined screening 
alone, because the additional costs for cfDNA testing 
would be counterbalanced by the reduction in costs of 
invasive testing. In addition, the overall cfDNA test fail-
ure rate would be lower compared to universal cfDNA 
screening because the test would be offered to a smaller 
proportion of the population. A screening strategy based 
on universal cfDNA screening alone or in combination 
with ultrasound would double the costs compared to 
contingent screening, with a similar number of invasive 
procedures (Table 4).
A strength of this study is that we examined a large 
cohort of twin pregnancies undergoing first-trimester 
combined screening to assess both clinical and eco-
nomic implications of the different screening strategies. 
The main limitations are the small number of fetuses 
with chromosomal abnormalities and the lack of infor-
mation on cfDNA testing results. Therefore, our data 
cannot be used to examine differences in the DR for 
common trisomies between the different strategies, and 
future larger studies are required to investigate this as-
pect further. 
From a clinical perspective, our results can be useful 
to clinicians, hospitals, and health authorities to select 
the preferred strategy in screening for aneuploidies in 
twin pregnancies, according to service availability and 
economic resources.
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